A Phase 3 interventional study of Ramucirumab and Paclitaxel in Gastroesophageal Junction Adenocarcinoma and Gastric Adenocarcinoma, sponsored by Eli Lilly and Company. Completed at 32 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 mg/kg ramucirumab was administered as an intravenous infusion (IV) on days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on days 1, 8, and 15 of every 28-day cycle. Participants may continue on treatment until discontinuation criteria were met.
Drug: Ramucirumab · Drug: Paclitaxel
Placebo was administered at a volume equivalent to a dose of 8 mg/kg by IV on Days 1 and 15, in combination with 80 mg/m² paclitaxel administered by IV on Days 1, 8, and 15 of a 28-day cycle. Participants may continue on treatment until discontinuation criteria were met.
Drug: Paclitaxel · Drug: Placebo
Administered IV
Also known as: LY3009806
Administered IV
Administered IV
Progression Free Survival (PFS)
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease or Death from Any Cause (Up To 30 Months)
Overall Survival (OS)
OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
Time frame: Randomization to Date of Death from Any Cause (Up To 37 Months)
Time to Progression (TTP)
TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
Time frame: Randomization to the Date of the First Radiographically Documented Progressive Disease (Up To 30 Months)
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Randomization to Objective Disease Progression (Up To 30 Months)
Duration of Objective Response (DoR)
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
Time frame: Date of Objective Response to the Date of the First Radiographically Documented Progressive Disease or Death Due to Any Cause (Up To 24 Months)
Best Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Worst Change From Baseline on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state.
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
Time frame: Baseline, 30 Days After Treatment Discontinuation (Up To 20 Months)
| Milestone | 8 Milligram/Kilogram (mg/kg) Ramucirumab + 80 mg/Square Meter (mg/m²) Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Started | 294 | 146 |
| Received at least 1 dose of study drug | 293 | 145 |
| Completed | 246 | 123 |
| Not completed | 48 | 23 |
| Withdrew: Enrolled/randomized, but never treated | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 3 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Sponsor decision | 32 | 13 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Withdrew: Discontinued from treatment but refused follow-up | 2 | 1 |
| Withdrew: Ended extension period | 3 | 0 |
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.
| Months | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Progression Free Survival (PFS) | 4.14 (3.71 to 4.30) | 3.15 (2.83 to 4.14) |
OS defined as the time from randomization to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.
| Months | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Overall Survival (OS) | 8.71 (7.98 to 9.49) | 7.92 (6.31 to 9.10) |
TTP was time from the date of randomization to the date of radiographic progression (according to RECIST v.1.1). If a participant died due to any reason without radiographic progression, TTP is censored at the last adequate tumor assessment. Target lesions: Progressive Disease (PD): At least a 20% increase in the sum of diameters of lesions vs the smallest sum on study (the sum must also demonstrate an absolute increase of at least 5 mm); or the appearance of new lesion(s). Non target lesions: PD: Unequivocal progression of existing lesions or the appearance of new lesion(s).
| Months | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Time to Progression (TTP) | 4.27 (4.14 to 5.52) | 4.07 (2.92 to 4.17) |
ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Percentage of participants | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) | 26.5 (21.6 to 32.0) | 21.9 (15.5 to 29.5) |
DOR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date. PD was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.
| Months | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Duration of Objective Response (DoR) | 4.34 (3.12 to 5.22) | 2.83 (2.56 to 4.14) |
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. Least square (LS) mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
| Units on a scale | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Global health status | 5.30 ± 1.18 | 8.43 ± 1.56 |
| Functional scale: Physical functioning | 1.09 ± 0.82 | 1.20 ± 1.10 |
| Functional scale: Role functioning | 0.60 ± 1.13 | 1.27 ± 1.49 |
| Functional scale: Emotional functioning | 5.89 ± 0.90 | 4.72 ± 1.19 |
| Functional scale: Cognitive functioning | 2.87 ± 0.84 | 2.12 ± 1.11 |
| Functional scale: Social functioning | 2.71 ± 1.19 | 2.98 ± 1.59 |
| Symptom scale: Fatigue | -4.20 ± 1.14 | -5.63 ± 1.51 |
| Symptom scale: Nausea and vomiting | -4.84 ± 0.77 | -3.80 ± 1.03 |
| Symptom scale: Pain | -6.89 ± 1.07 | -7.01 ± 1.43 |
| Symptom scale: Dyspnea | -2.18 ± 0.95 | -2.65 ± 1.27 |
| Symptom scale: Insomnia | -5.73 ± 1.18 | -7.06 ± 1.57 |
| Symptom scale: Appetite loss | -7.84 ± 1.30 | -10.26 ± 1.73 |
| Symptom scale: Constipation | -6.35 ± 1.11 | -5.41 ± 1.48 |
| Symptom scale: Diarrhea | -2.51 ± 0.86 | -3.03 ± 1.14 |
| Symptom scale: Financial difficulties | -8.49 ± 1.60 | -8.12 ± 2.13 |
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms. LS Mean value of changing from baseline to short-term follow up was estimated from the mixed model that was controlled for Treatment, visit, Treatment\*Visit and baseline.
| Units on a scale | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Global health status | -14.42 ± 1.32 | -9.83 ± 1.75 |
| Functional scale: Physical functioning | -14.31 ± 1.30 | -11.71 ± 1.73 |
| Functional scale: Role functioning | -18.46 ± 1.72 | -14.39 ± 2.28 |
| Functional scale: Emotional functioning | -9.80 ± 1.30 | -6.77 ± 1.72 |
| Functional scale: Cognitive functioning | -13.66 ± 1.40 | -12.08 ± 1.85 |
| Functional scale: Social functioning | -17.05 ± 1.73 | -16.52 ± 2.30 |
| Symptom scale: Fatigue | 15.28 ± 1.36 | 10.17 ± 1.80 |
| Symptom scale: Nausea and vomiting | 8.57 ± 1.46 | 8.66 ± 1.95 |
| Symptom scale: Pain | 14.01 ± 1.50 | 10.11 ± 2.00 |
| Symptom scale: Dyspnea | 16.58 ± 1.51 | 8.34 ± 2.01 |
| Symptom scale: Insomnia | 14.14 ± 1.74 | 7.97 ± 2.32 |
| Symptom scale: Appetite loss | 17.06 ± 1.85 | 11.11 ± 2.46 |
| Symptom scale: Constipation | 8.39 ± 1.57 | 6.58 ± 2.08 |
| Symptom scale: Diarrhea | 13.41 ± 1.39 | 5.67 ± 1.85 |
| Symptom scale: Financial difficulties | 10.11 ± 1.80 | 9.32 ± 2.39 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. A regression equation defines a utility value for these health states to generate an index score. The possible values for index score range from -0.594 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 1 represents the best possible health state.
| Units on a scale | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L) Index Score | -0.1351 ± 0.2472 | -0.1303 ± 0.1765 |
EQ-5D-3L is a descriptive system of health-related quality of life states consisting of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and each of which has 3 levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension. The EQ-5D VAS is used to record a participant's rating for his/her current health-related quality of life state on the day of questionnaire administration and is captured on a scale of 0 (worst imaginable health state) to 100 (best imaginable health state).
| millimeter (mm) | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Change From Baseline in Participant-Reported EQ-5D-3L Visual Analog Scale (VAS) Score | -9.6 ± 20.11 | -8.6 ± 15.88 |
Collected over Adverse Events: Randomization Up To 26 Months; All-Cause Mortality: Randomization to Date of Death from Any Cause (Up To 37 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | 246/294 (83.7%) | 100/293 (34.1%) | 287/293 (98%) |
| Placebo + 80 mg/m² Paclitaxel | 123/146 (84.2%) | 37/145 (25.5%) | 143/145 (98.6%) |
| Event | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| Neutrophil count decreasedInvestigations | 15/293 | 3/145 |
| Febrile neutropeniaBlood and lymphatic system disorders | 13/293 | 0/145 |
| White blood cell count decreasedInvestigations | 12/293 | 2/145 |
| PneumoniaInfections and infestations | 10/293 | 5/145 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 9/293 | 1/145 |
| Platelet count decreasedInvestigations | 9/293 | 0/145 |
| AnaemiaBlood and lymphatic system disorders | 6/293 | 4/145 |
| VomitingGastrointestinal disorders | 4/293 | 4/145 |
| PyrexiaGeneral disorders | 7/293 | 2/145 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/293 | 3/145 |
| Event | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel |
|---|---|---|
| White blood cell count decreasedInvestigations | 227/293 | 107/145 |
| Neutrophil count decreasedInvestigations | 223/293 | 102/145 |
| AnaemiaBlood and lymphatic system disorders | 195/293 | 94/145 |
| AlopeciaSkin and subcutaneous tissue disorders | 83/293 | 55/145 |
| Aspartate aminotransferase increasedInvestigations | 100/293 | 35/145 |
| ProteinuriaRenal and urinary disorders | 99/293 | 31/145 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 90/293 | 31/145 |
| Alanine aminotransferase increasedInvestigations | 88/293 | 31/145 |
| Platelet count decreasedInvestigations | 88/293 | 17/145 |
| Decreased appetiteMetabolism and nutrition disorders | 81/293 | 32/145 |
All randomized participants.
| Age, Continuous(years) | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel | Total |
|---|---|---|---|
| Mean | 56.00 ± 11.49 | 56.20 ± 11.12 | 56.10 ± 11.35 |
| Sex: Female, Male(Participants) | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel | Total |
|---|---|---|---|
| Female | 89 | 50 | 139 |
| Male | 205 | 96 | 301 |
| Race (NIH/OMB)(Participants) | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 290 | 145 | 435 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 1 | 0 | 1 |
| More than one race | 3 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 8 mg/kg Ramucirumab + 80 mg/m² Paclitaxel | Placebo + 80 mg/m² Paclitaxel | Total |
|---|---|---|---|
| China | 257 | 135 | 392 |
| Malaysia | 18 | 7 | 25 |
| Philippines | 6 | 2 | 8 |
| Thailand | 13 | 2 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Mar 2017 to primary completion in Jun 2020, 39 months.
Results were first posted in Aug 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab